Tasquinimod 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
Tasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
More Information Supplier PageTasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
More Information Supplier PageTasquinimod is an orally active antiangiogenic agent by allosterically inhibiting HDAC4 signalling.
More Information Supplier PageABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity.
More Information Supplier PageAvanafil is a PDE5 Inhibitor for the Treatment of Erectile Dysfunction
More Information Supplier PageMK-3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists.
More Information Supplier PageMelanotan II is a high affinity melanocortin receptor agonist (Ki values are 0.67, 6.6, 34 and 46 nM for MC1, MC4, MC3 and MC5 receptors respectively).
More Information Supplier PageEndoxifen is a secondary metabolite of tamoxifen. It is a primary metabolite responsible for the effectiveness of tamoxifen in ER-positive breast cancer.
More Information Supplier PageEndoxifen is a secondary metabolite of tamoxifen. It is a primary metabolite responsible for the effectiveness of tamoxifen in ER-positive breast cancer.
More Information Supplier PageEndoxifen is a secondary metabolite of tamoxifen. It is a primary metabolite responsible for the effectiveness of tamoxifen in ER-positive breast cancer.
More Information Supplier PageMBX-2982 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
More Information Supplier Page